Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 15, Issue 6, 2014, Pages 441-447

  He, Yan Yan ^a,b   Zhang, Xu Chao ^b   Yang, Jin Ji ^b   Niu, Fei Yu ^a,b   Zeng, Zhu ^b   Yan, Hong Hong ^b   Xu, Chong Rui ^b   Guan, Ji Lin ^b   Zhong, Wen Zhao ^b   Yang, Lu Lu ^a,b   Guo, Long Hua ^a,b   Wu, Yi Long ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Genotyping; Metastatic organ site; Non small cell lung cancer; Overall survival; Prognosis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER GENETICS; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMALL CELL LUNG CANCER; SMOKING; COHORT ANALYSIS; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84908206884     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.06.006     Document Type: Article

References (38)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
3. K. Kelly, J. Crowley, and P.J. Bunn Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
4. F.C. Detterbeck, D.J. Boffa, and L.T. Tanoue The new lung cancer staging system Chest 136 2009 260 271
5. P.E. Postmus, E. Brambilla, and K. Chansky The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer J Thorac Oncol 2 2007 686 693
6. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
7. T. Mitsudomi, S. Morita, and Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
8. C. Zhou, Y.L. Wu, and G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
9. R. Rosell, E. Carcereny, and R. Gervais Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
10. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
11. L.V. Sequist, J.C. Yang, and N. Yamamoto Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 2013 3327 3334
12. Y.L. Wu, C. Zhou, and C.P. Hu Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Lancet Oncol 15 2014 213 222
13. A.T. Shaw, D.W. Kim, and K. Nakagawa Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
14. D.R. Camidge, Y.J. Bang, and E.L. Kwak Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
15. D.-W. Kim, M.-J. Ahn, and Y. Shi Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol 30 suppl 2012 7533
16. M.R. MacManus, R. Hicks, and R. Fisher FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy - survival correlates with metastatic disease burden Acta Oncol 42 2003 48 54
17. Y. Oh, S. Taylor, and B.N. Bekele Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases Cancer 115 2009 2930 2938
18. J.H. Park, T.M. Kim, and B. Keam Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib Clin Lung Cancer 14 2013 383 389
19. T. Hothorn, and A. Zeileis Generalized maximally selected statistics Biometrics 64 2008 1263 1269
20. P. Goldstraw, J. Crowley, and K. Chansky The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2 2007 706 714
21. B.E. Johnson, M.G. Kris, and L.D. Berry A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: the Lung Cancer Mutation Consortium (LCMC) [abstract] J Clin Oncol 31 suppl 2013 8019
22. T. Hoang, R. Xu, and J.H. Schiller Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data J Clin Oncol 23 2005 175 183
23. K.S. Albain, J.J. Crowley, and M. LeBlanc Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience J Clin Oncol 9 1991 1618 1626
24. O. Mercier, E. Fadel, and M. de Perrot Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer J Thorac Cardiovasc Surg 130 2005 136 140
25. P. Mordant, A. Arame, and F. De Dominicis Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer? Eur J Cardiothorac Surg 41 2012 617 622
26. H. Porte, J. Siat, and B. Guibert Resection of adrenal metastases from non-small cell lung cancer: a multicenter study Ann Thorac Surg 71 2001 981 985
27. Y. Oshiro, Y. Takeda, and S. Hirano Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer Am J Clin Oncol 34 2011 249 253
28. A. Nagashima, Y. Abe, and S. Yamada Long-term survival after surgical resection of liver metastasis from lung cancer Jpn J Thorac Cardiovasc Surg 52 2004 311 313
29. D.W. Andrews, C.B. Scott, and P.W. Sperduto Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial Lancet 363 2004 1665 1672
30. R.A. Patchell, P.A. Tibbs, and J.W. Walsh A randomized trial of surgery in the treatment of single metastases to the brain N Engl J Med 322 1990 494 500
31. C.J. Vecht, H. Haaxma-Reiche, and E.M. Noordijk Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33 1993 583 590
32. D. De Ruysscher, R. Wanders, and A. van Baardwijk Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450) J Thorac Oncol 7 2012 1547 1555
33. G.H. Griffioen, D. Toguri, and M. Dahele Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors Lung Cancer 82 2013 95 102
34. T. Yano, A. Haro, and T. Yoshida Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer J Surg Oncol 102 2010 852 855
35. H.A. Yu, C.S. Sima, and J. Huang Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors J Thorac Oncol 8 2013 346 351
36. A.J. Weickhardt, B. Scheier, and J.M. Burke Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer J Thorac Oncol 7 2012 1807 1814
37. G.N. Gan, A.J. Weickhardt, and B. Scheier Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib Int J Radiat Oncol Biol Phys 88 2014 892 898
38. J.J. Yang, H.J. Chen, and H.H. Yan Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer Lung Cancer 79 2013 33 39